BiotechTube

Triptorelin

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Normal Oocyte Donors

Conditions

Normal Oocyte Donors

Trial Timeline

Aug 1, 2014 → Mar 1, 2015

NCT ID
NCT02208986

About Triptorelin

Triptorelin is a pre-clinical stage product being developed by Merck for Normal Oocyte Donors. The current trial status is completed. This product is registered under clinical trial identifier NCT02208986. Target conditions include Normal Oocyte Donors.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02208986Pre-clinicalCompleted

Competing Products

20 competing products in Normal Oocyte Donors

See all competitors
ProductCompanyStageHype Score
RoxadustatAstellas PharmaPhase 1
33
DonepezilEisaiApproved
85
eribulin mesylateEisaiPhase 2
52
Lurasidone HClSumitomo PharmaPhase 1
33
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
85
Temozolomide + VorinostatMerckPhase 2
52
LDE225NovartisPhase 1
33
LDK378NovartisPhase 1
33
cyclosporine micro-emulsionNovartisApproved
85
LDK378NovartisPhase 1
33
LEE011NovartisPhase 1
33
LEE011NovartisPhase 1
33
mycophenolate mofetilRochePhase 1
33
filgrastimAmgenPre-clinical
22
PF-06423264PfizerPhase 1
32
PF-05221304PfizerPhase 1
32
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose SolutionBristol Myers SquibbPhase 1
32
tolebrutinibSanofiPhase 1
32
Venglustat (GZ402671)SanofiPhase 1
32
RilzabrutinibSanofiPhase 1
32

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85